The Trump administration’s decision to reclassify state-authorized medical cannabis products represents an evolution in US federal drug policy. This move, which acknowledges state-licensed medical cannabis providers, marks a shift from the federal government’s long-held position regarding cannabis’s legitimate medical utility. While welcomed by advocates, the medical cannabis rescheduling order is viewed by some industry observers as an initial step that does not fully resolve the existing state-federal conflicts.
Federal Policy Shift on Medical Cannabis
For over five decades, the US federal government maintained that marijuana lacked legitimate medical utility and classified it alongside substances like heroin under federal law. This stance often led to enforcement actions that impacted physicians discussing medical cannabis options with patients. However, a growing scientific, political, and public consensus has driven a re-evaluation of this policy.
Currently, forty US states have legalised physician-authorised access to medicinal cannabis products, with many of these state-level programs operating for decades. Data indicates that these programs have not been repealed, suggesting their continued operation and minimal abuses. A significant majority of health professionals, approximately 69 percent of family physicians, nurse practitioners, and other clinicians nationwide, now acknowledge that cannabis has established medical uses, with over one-quarter reporting they have discussed it with patients, according to an op-ed published by Marijuana Moment.
Further supporting this shift, an extensive 250-page review issued by the Department of Health and Human Services (HHS) in 2023 concluded that “No safety concerns were identified in our review that would indicate that the medical use of marijuana poses unacceptably high safety risks for the indications where there is some credible scientific evidence supporting its therapeutic use.” This review also noted that more than 6 million patients utilise medical cannabis under physician supervision, particularly for the mitigation and management of chronic pain. This aligns with findings from researchers affiliated with the National Academy of Sciences nearly a decade prior, which determined “conclusive evidence” of cannabis’s potential in managing chronic pain conditions.
Limitations of the Rescheduling Order
Despite the significance of the medical cannabis rescheduling order, it does not provide comprehensive relief or fully harmonise state and federal marijuana policy. The order does not extend aid to patients residing in the ten US states that currently do not regulate medical cannabis use. These individuals continue to face risks of arrest and prosecution for cannabis-related activities.
Furthermore, the federal policy change offers no legal remedies for the thousands of businesses or millions of consumers in the twenty-four states that have legalised adult-use recreational marijuana. Under federal law, individuals and entities involved in the sale or consumption of cannabis in these states remain technically in violation, despite adherence to state regulations.
Calls for Comprehensive Federal Reform
To fully address the state-federal conflict and grant state governments explicit authority to establish their own adult-use cannabis regulatory policies, similar to alcohol, some advocates argue that cannabis must be removed from the Controlled Substances Act (CSA) entirely. Paul Armentano, Deputy Director for NORML, articulated this perspective in the Marijuana Moment op-ed, stating that such a move would affirm principles of federalism and align with public sentiment regarding government intrusion.
This approach would significantly alter the legal landscape for cannabis, allowing states greater autonomy in regulating both medical and adult-use markets without federal preemption. The current rescheduling order, while acknowledging medical utility, maintains cannabis within the federal controlled substances framework, albeit at a lower schedule, which continues to create regulatory and legal complexities for the industry and patients alike.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
